RESUMEN
OBJECTIVE: While biologics have been used for the patients with psoriatic arthritis, there remains to be unknown concerning long-term retention rates. This study aims to present real-world data about long-term retention rates of biologics for the patients with psoriatic arthritis, and to undertake an analysis of the contributing factors. METHODS: We examined retention rates and the reasons for discontinuation for biologics (adalimumab, certolizumab pegol, secukinumab, and ixekizumab) in 146 prescriptions (of which, 109 prescriptions were as naive) at our hospital since March 2010. RESULTS: Throughout the entire course of the study, the 10-year retention rates were approximately 70% for adalimumab, 50% for ixekizumab, and 40% for secukinumab. When evaluating retention rates in the biologic-naïve subgroups, the 10-year retention rates were all approximately 70%. Regarding certolizumab pegol, the 3-year retention rate was approximately 75%. For adalimumab, a higher degree of arthritis at the initiation of treatment was found to correlate with an increased likelihood of secondary inefficacy. The main reason for discontinuation was secondary inefficacy, except for ixekizumab. CONCLUSIONS: Each biologic exhibited a favourable long-term retention rate. The main reason for discontinuation was secondary inefficacy. Regarding adalimumab, secondary inefficacy was linked to the extent of arthritis upon treatment initiation.
Asunto(s)
Anticuerpos Monoclonales Humanizados , Antirreumáticos , Artritis Psoriásica , Interleucina-17 , Humanos , Artritis Psoriásica/tratamiento farmacológico , Artritis Psoriásica/inmunología , Masculino , Femenino , Persona de Mediana Edad , Interleucina-17/antagonistas & inhibidores , Interleucina-17/inmunología , Anticuerpos Monoclonales Humanizados/uso terapéutico , Adulto , Antirreumáticos/uso terapéutico , Adalimumab/uso terapéutico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Certolizumab Pegol/uso terapéutico , Anciano , Productos Biológicos/uso terapéutico , Resultado del TratamientoRESUMEN
Pustulotic arthro-osteitis (PAO) is a rare chronic inflammatory arthropathy associated with palmoplantar pustulosis. The pathogenesis of PAO remains unclear. The most common musculoskeletal involvement in PAO is ossification of the sternoclavicular joints. A combination of parietal inflammation and hyperostosis-induced mechanical compression in this region is hypothesized to contribute to multiple venous thrombosis. Here, we present a 66-year-old man with PAO-associated multiple venous occlusion who was successfully treated with guselkumab. We also discuss its clinical manifestation and cause by reviewing the literature.